36 articles with Oncopeptides AB
Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company's incentive programs.
Oncopeptides has previously communicated a target enrollment of 150 patients in the study before the end of September, which now has been achieved.
Oncopeptides AB announces that all stock options held by management team members under the Employee Stock Option Program 2012/2019 with associated warrants have been exercised.
New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop
Oncopeptides AB announced updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International Myeloma Workshop meeting in Boston, Massachusetts, USA.
The data presented are encouraging and show continued momentum for Oncopeptides' melflufen.
New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th
Oncopeptides AB announced that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th International Myeloma Workshop meeting on September 15, Boston, Massachusetts, USA.
In late August it was announced that Klaas Bakker was appointed as the new Chief Medical Officer for Oncopeptides.
Oncopeptides AB announces that Klaas Bakker has been appointed as the new Chief Medical Officer for Oncopeptides, starting in November.
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).
The share issue entails a dilution of approximately 9.3 percent of the number of shares and votes in the company.
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Oncopeptides AB announced updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial.
New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
Oncopeptides AB, announced new data presented at the 24th Congress of the European Hematology Association in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.
Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting
Oncopeptides AB, announces that the company will make a review and update on the presented data from the European Hematology Meeting on Monday, June 17, 2019, at. 09:00.
New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting
The data demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated patients with relapsed/refractory multiple myeloma (RRMM).
Oncopeptides to Present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST
Oncopeptides AB announced that they will attend the Jefferies annual Healthcare Conference in New York between June 4-7th and make a plenum presentation on June 7th 11.30am EST.
The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.
Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed.
Oncopeptides AB announced that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
Oncopeptides AB announced that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association meeting.